Matti Karvanen
- Molecular Medicine top 0.5%
- Pharmacology top 1%
- Epidemiology top 10%
- Applied Microbiology and Biotechnology top 2%
- Pollution top 10%
- Co-authors
- Otto CarsLena E. FribergDiamantis PlachourasApostolos ArmaganidisHelen GiamarellouEvangelos PapadomichelakisIlias KaraiskosAnastasia Antoniadou
- Topics
- Antibiotic Resistance in Bacteria (12 papers)Antibiotics Pharmacokinetics and Efficacy (9 papers)Pneumonia and Respiratory Infections (5 papers)
In The Last Decade
Matti Karvanen
12 papers receiving 919 citations
Peers
Comparison fields: 5 of 57
- Molecular Medicine 832
- Pharmacology 734
- Epidemiology 454
- Applied Microbiology and Biotechnology 112
- Pollution 111
Countries citing papers authored by Matti Karvanen
This map shows the geographic impact of Matti Karvanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matti Karvanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matti Karvanen more than expected).
Fields of papers citing papers by Matti Karvanen
This network shows the impact of papers produced by Matti Karvanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matti Karvanen. The network helps show where Matti Karvanen may publish in the future.
Co-authorship network of co-authors of Matti Karvanen
This figure shows the co-authorship network connecting the top 25 collaborators of Matti Karvanen. A scholar is included among the top collaborators of Matti Karvanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matti Karvanen. Matti Karvanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. | 1 |
| 3 | 67 | |
| 4 | 20 | |
| 5 | 43 | |
| 6 | Optimization of Colistin Dosage in the Treatment of Multiresistant Gram-negative Infections | 9 |
| 7 | 1 | |
| 8 | 67 | |
| 9 | 173 | |
| 10 | 64 | |
| 11 | 395 | |
| 12 | 95 |
About Matti Karvanen
Matti Karvanen is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology and Pharmacology, having authored 12 papers that have together received 939 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers) and Pneumonia and Respiratory Infections (5 papers). The work is most often cited by research in Molecular Medicine (832 citations), Applied Microbiology and Biotechnology (112 citations) and Pharmacology (734 citations). Matti Karvanen has collaborated with scholars based in Sweden, Greece and Malaysia. Frequent co-authors include Otto Cars, Lena E. Friberg, Diamantis Plachouras, Apostolos Armaganidis, Helen Giamarellou, Evangelos Papadomichelakis, Ilias Karaiskos, Anastasia Antoniadou, Britt Jansson and Iraklis Tsangaris. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Pharmacology & Therapeutics and Journal of Antimicrobial Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.